NEW YORK (GenomeWeb) – Enzo Life Sciences has entered into a settlement and license agreement with Hologic, Grifols, and Grifols Diagnostic Solutions, Enzo disclosed in a recent filing with the US Securities and Exchange Commission.
The agreement settles all outstanding patent disputes among the parties and includes a one-time payment of $14 million to Enzo in exchange for fully paid-up, worldwide licenses to Hologic and Grifols, according to the SEC document.
The dispute centered on Enzo's US Patent No. 6,221,581, covering modified nucleotides for use in diagnostic and therapeutic applications.
In its SEC filing, Enzo said that the settlement and license agreement should not be considered an admission of liability or responsibility, or lack thereof, on the part of Enzo, Hologic, or Grifols.
In 2017, Enzo had announced that one of its patents at the center of a long-running intellectual property dispute has been found invalid by a federal judge.
Enzo originally sued several companies for allegedly infringing some of its patents. A handful of defendants settled with Enzo in recent years, while others sought to have Enzo's patents invalidated.